Taiho inks exclusive license deal with Haihe Biopharma

16 October 2025

Japanese drugmaker Taiho Pharmaceutical, a subsidiary of Otsuka (TYO: 4578), and China-based Haihe Biopharma have entered into an exclusive license agreement regarding the development, manufacturing and commercialization of the PI3Kα (phosphatidylinositol 3-kinase alpha) inhibitor risovalisib (CYH33).

Risovalisib is currently being submitted for manufacturing and marketing approval in Japan as a treatment for ovarian clear cell carcinoma by Haihe Biopharma KK, a fully-owned affiliate of Haihe.

Under the license agreement, Taiho will gain exclusive rights in Japan to develop, manufacture and commercialize risovalisib, and Haihe will receive an undisclosed upfront payment, development and sales milestones, as well as royalties based on sales revenue from Taiho.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK